107 related articles for article (PubMed ID: 12132666)
1. Isolation of a novel peptide homing to tumor-derived neovasculature that suppresses tumor growth.
Asai T; Fukatsu H; Kuromi K; Ogino K; Tanaka M; Oku N; Taki T
Biol Pharm Bull; 2002 Jul; 25(7):904-6. PubMed ID: 12132666
[TBL] [Abstract][Full Text] [Related]
2. Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels.
Asai T; Nagatsuka M; Kuromi K; Yamakawa S; Kurohane K; Ogino K; Tanaka M; Taki T; Oku N
FEBS Lett; 2002 Jan; 510(3):206-10. PubMed ID: 11801255
[TBL] [Abstract][Full Text] [Related]
3. Anti-neovascular therapy using novel peptides homing to angiogenic vessels.
Oku N; Asai T; Watanabe K; Kuromi K; Nagatsuka M; Kurohane K; Kikkawa H; Ogino K; Tanaka M; Ishikawa D; Tsukada H; Momose M; Nakayama J; Taki T
Oncogene; 2002 Apr; 21(17):2662-9. PubMed ID: 11965539
[TBL] [Abstract][Full Text] [Related]
4. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase.
Kondo M; Asai T; Katanasaka Y; Sadzuka Y; Tsukada H; Ogino K; Taki T; Baba K; Oku N
Int J Cancer; 2004 Jan; 108(2):301-6. PubMed ID: 14639619
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
6. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells.
Yeh CH; Peng HC; Yang RS; Huang TF
Mol Pharmacol; 2001 May; 59(5):1333-42. PubMed ID: 11306719
[TBL] [Abstract][Full Text] [Related]
7. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth.
He GA; Luo JX; Zhang TY; Wang FY; Li RF
Biochem Biophys Res Commun; 2003 Dec; 312(3):801-5. PubMed ID: 14680836
[TBL] [Abstract][Full Text] [Related]
8. A novel vascular-targeting peptide for gastric cancer delivers low-dose TNFα to normalize the blood vessels and improve the anti-cancer efficiency of 5-fluorouracil.
Lu L; Li ZJ; Li LF; Shen J; Zhang L; Li MX; Xiao ZG; Wang JH; Cho CH
Peptides; 2017 Nov; 97():54-63. PubMed ID: 28970092
[TBL] [Abstract][Full Text] [Related]
9. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
10. Introduction of midkine gene into human bladder cancer cells enhances their malignant phenotype but increases their sensitivity to antiangiogenic therapy.
Muramaki M; Miyake H; Hara I; Kamidono S
Clin Cancer Res; 2003 Nov; 9(14):5152-60. PubMed ID: 14613994
[TBL] [Abstract][Full Text] [Related]
11. Discovery and development of anti-angiogenic peptides: A structural link.
Dings RP; Nesmelova I; Griffioen AW; Mayo KH
Angiogenesis; 2003; 6(2):83-91. PubMed ID: 14739615
[TBL] [Abstract][Full Text] [Related]
12. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.
Lu D; Jimenez X; Zhang H; Bohlen P; Witte L; Zhu Z
Int J Cancer; 2002 Jan; 97(3):393-9. PubMed ID: 11774295
[TBL] [Abstract][Full Text] [Related]
13. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic gene therapy for hepatocellular carcinoma using angiostatin gene.
Ishikawa H; Nakao K; Matsumoto K; Ichikawa T; Hamasaki K; Nakata K; Eguchi K
Hepatology; 2003 Mar; 37(3):696-704. PubMed ID: 12601367
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
Kimura Y; Sumiyoshi M; Baba K
Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
[TBL] [Abstract][Full Text] [Related]
16. (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis.
Yamakawa S; Asai T; Uchida T; Matsukawa M; Akizawa T; Oku N
Cancer Lett; 2004 Jul; 210(1):47-55. PubMed ID: 15172120
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
18. A new phage-display tumor-homing peptide fused to antiangiogenic peptide generates a novel bioactive molecule with antimelanoma activity.
Matsuo AL; Juliano MA; Figueiredo CR; Batista WL; Tanaka AS; Travassos LR
Mol Cancer Res; 2011 Nov; 9(11):1471-8. PubMed ID: 21900362
[TBL] [Abstract][Full Text] [Related]
19. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
[TBL] [Abstract][Full Text] [Related]
20. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells.
He GA; Luo JX; Zhang TY; Hu ZS; Wang FY
Biochem Biophys Res Commun; 2004 May; 318(2):354-60. PubMed ID: 15120609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
